{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:26:31Z","timestamp":1794835591103,"version":"4.9.1"},"reference-count":31,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Nearly 80% of the warfarin-treated patients with ICH had an INR within or below therapeutic range around 2 weeks before the event. We can reduce ICH by using apixaban rather than warfarin and by avoiding concomitant aspirin, especially in patients with older age.<\/jats:p>","DOI":"10.1182\/blood-2016-08-731638","type":"journal-article","created":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T20:25:21Z","timestamp":1490819121000},"page":"2980-2987","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":105,"title":["Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy"],"prefix":"10.1182","volume":"129","author":[{"given":"Renato D.","family":"Lopes","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Duke Health, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia O.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke Health, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Kolls","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke Health, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Wojdyla","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke Health, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl D.","family":"Bushnell","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wake Forest School of Medicine, Winston Salem, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hanna","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Donald","family":"Easton","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laine","family":"Thomas","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke Health, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center and"},{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana M.","family":"Al-Khatib","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke Health, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Held","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center and"},{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Gabriel Melo de Barros e Silva","sequence":"additional","affiliation":[{"name":"Brazilian Clinical Research Institute, Sao Paulo, Brazil; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke Health, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke Health, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"Department of Neurology and Headache Center, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111903313907100_B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2008.05.001","article-title":"Warfarin and intracranial haemorrhage","volume":"23","author":"Appelboam","year":"2009","journal-title":"Blood Rev"},{"issue":"8","key":"2019111903313907100_B2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","article-title":"Death and disability from warfarin-associated intracranial and extracranial hemorrhages","volume":"120","author":"Fang","year":"2007","journal-title":"Am J Med"},{"issue":"20","key":"2019111903313907100_B3","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/eurheartj\/ehu463","article-title":"Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial","volume":"36","author":"Held","year":"2015","journal-title":"Eur Heart J"},{"issue":"2","key":"2019111903313907100_B4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00415-011-6153-3","article-title":"Oral anticoagulant-associated intracerebral hemorrhage","volume":"259","author":"Cervera","year":"2012","journal-title":"J Neurol"},{"issue":"3","key":"2019111903313907100_B5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.thromres.2015.07.001","article-title":"Intracranial haemorrhage in patients treated with direct oral anticoagulants","volume":"136","author":"Beynon","year":"2015","journal-title":"Thromb Res"},{"issue":"4","key":"2019111903313907100_B6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/ene.12352","article-title":"Higher baseline international normalized ratio value correlates with higher mortality in intracerebral hemorrhage during warfarin use","volume":"21","author":"Curtze","year":"2014","journal-title":"Eur J Neurol"},{"issue":"10","key":"2019111903313907100_B7","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.06.031","article-title":"Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation","volume":"23","author":"Grysiewicz","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"6","key":"2019111903313907100_B8","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","article-title":"Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial","volume":"43","author":"Hart","year":"2012","journal-title":"Stroke"},{"issue":"5","key":"2019111903313907100_B9","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","article-title":"Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation","volume":"45","author":"Hankey","year":"2014","journal-title":"Stroke"},{"issue":"8","key":"2019111903313907100_B10","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1161\/STROKEAHA.114.006025","article-title":"Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48","volume":"45","author":"Giugliano","year":"2014","journal-title":"Stroke"},{"issue":"11","key":"2019111903313907100_B11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111903313907100_B12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"issue":"3","key":"2019111903313907100_B13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.STR.0000258004.64840.0b","article-title":"Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials","volume":"38","author":"Akins","year":"2007","journal-title":"Stroke"},{"issue":"12","key":"2019111903313907100_B14","first-page":"852","article-title":"Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1","volume":"38","author":"Diener","year":"2017","journal-title":"Eur Heart J"},{"issue":"4","key":"2019111903313907100_B15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"issue":"7","key":"2019111903313907100_B16","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/01.STR.0000170642.39876.f2","article-title":"Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas","volume":"36","author":"Hart","year":"2005","journal-title":"Stroke"},{"issue":"6","key":"2019111903313907100_B17","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0149-2918(03)80167-4","article-title":"Factors influencing physicians\u2019 reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey","volume":"25","author":"Gross","year":"2003","journal-title":"Clin Ther"},{"issue":"6","key":"2019111903313907100_B18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.amjmed.2005.02.022","article-title":"Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall","volume":"118","author":"Gage","year":"2005","journal-title":"Am J Med"},{"issue":"5","key":"2019111903313907100_B19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/0003-4819-150-5-200903030-00005","article-title":"Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial","volume":"150","author":"Crowther","year":"2009","journal-title":"Ann Intern Med"},{"issue":"8","key":"2019111903313907100_B20","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"issue":"22","key":"2019111903313907100_B21","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111903313907100_B22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111903313907100_B23","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111903313907100_B24","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1161\/CIRCULATIONAHA.113.002332","article-title":"Management and outcomes of major bleeding during treatment with dabigatran or warfarin","volume":"128","author":"Majeed","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"2019111903313907100_B25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer-Westendorf","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111903313907100_B26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111903313907100_B27","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet Alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111903313907100_B28","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111903313907100_B29","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"issue":"9855","key":"2019111903313907100_B30","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial","volume":"380","author":"Lopes","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"2019111903313907100_B31","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes","volume":"63","author":"Hylek","year":"2014","journal-title":"J Am Coll Cardiol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/22\/2980\/1400722\/blood731638.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/22\/2980\/1400722\/blood731638.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:31:57Z","timestamp":1574134317000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/22\/2980\/36039\/Intracranial-hemorrhage-in-patients-with-atrial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":31,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-08-731638","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}